6.8
"Idorsia Begins Phase III Study of Selatogrel, a Fast-Acting, Self-administered Therapy for Heart Attacks; Paves Way for Potential Healthcare Breakthrough"
scrip.citeline.com
#
©
News Score
score the news, sort the news, rewrite the headlines
Leaderboard
Submit
About